These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 31500430)

  • 21. Current status of chemotherapy in metastatic pancreatic cancer.
    Wils JA
    Anticancer Res; 1989; 9(4):1027-31. PubMed ID: 2683988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Systemic chemotherapy for unresectable pancreatic cancer].
    Naruge D; Nagashima F; Furuse J
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():148-51. PubMed ID: 25857004
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant and neoadjuvant therapy for pancreatic cancer.
    Vinciguerra V
    Oncology (Williston Park); 2011 Feb; 25(2):192-3. PubMed ID: 21456392
    [No Abstract]   [Full Text] [Related]  

  • 24. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.
    Chen LT; Wang-Gillam A; Von Hoff DD; Bayever E; Belanger B
    Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203770
    [No Abstract]   [Full Text] [Related]  

  • 25. Systemic treatment of advanced pancreatic cancer--step by step progress.
    Seufferlein T
    Gut; 2013 May; 62(5):660-1. PubMed ID: 22952212
    [No Abstract]   [Full Text] [Related]  

  • 26. Expanding options for pancreatic cancer... so where do we go from here?
    Ko AH
    Oncology (Williston Park); 2014 Jan; 28(1):5. PubMed ID: 24683713
    [No Abstract]   [Full Text] [Related]  

  • 27. A case of pancreatic cancer achieving symptomatic improvement with systemic chemotherapy.
    Kosakamoto H; Okada S; Ueno H; Okusaka T; Ikeda M; Tanaka N; Yoshimori M; Matsuno Y
    Hepatogastroenterology; 1999; 46(28):2621-4. PubMed ID: 10522052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results.
    Teo M; McDermott RS
    Ann Oncol; 2013 Sep; 24(9):2462-3. PubMed ID: 23986547
    [No Abstract]   [Full Text] [Related]  

  • 29. A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer.
    Pacheco-Barcia V; Mondéjar Solís R; France T; Asselah J; Donnay O; Zogopoulos G; Bouganim N; Guo K; Rogado J; Martin E; Alcindor T; Colomer R
    Pancreas; 2019; 48(5):e45-e47. PubMed ID: 31090669
    [No Abstract]   [Full Text] [Related]  

  • 30. Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer.
    Sullivan KM; Kozuch PS
    Cancer J; 2012; 18(6):633-41. PubMed ID: 23187852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy in pancreatic cancer: a rational pursuit?
    Wils JA
    Anticancer Drugs; 1991 Feb; 2(1):3-10. PubMed ID: 1958849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy of pancreatic carcinoma.
    Harvey JH; Schein PS
    World J Surg; 1984 Dec; 8(6):935-9. PubMed ID: 6440373
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of pancreatic cancer].
    Mizumoto R; KitaT
    Gan No Rinsho; 1989 Jan; Spec No():329-36. PubMed ID: 2915484
    [No Abstract]   [Full Text] [Related]  

  • 35. Pancreatic cancer: how can we progress?
    Casper ES
    Eur J Cancer; 1993; 29A(2):171-2. PubMed ID: 8422277
    [No Abstract]   [Full Text] [Related]  

  • 36. Fluorouracil and mitomycin for pancreatic cancer.
    Bosch X
    Lancet Oncol; 2005 Sep; 6(9):644. PubMed ID: 16161265
    [No Abstract]   [Full Text] [Related]  

  • 37. [TH-302: a new hypoxia-activated cytostatic agent in pancreatic cancer treatment].
    Schmalz C; Dunst J
    Strahlenther Onkol; 2015 Oct; 191(10):819-20. PubMed ID: 26385861
    [No Abstract]   [Full Text] [Related]  

  • 38. Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Sasaki Y; Hamada K; Kaneta T; Takahashi T; Kubota Y; Ishida H; Ichikawa W
    Cancer Sci; 2015 Aug; 106(8):1100. PubMed ID: 26268893
    [No Abstract]   [Full Text] [Related]  

  • 39. [Concomitant chemoradiotherapy and preoperative radiotherapy in exocrine pancreatic adenocarcinoma].
    Mornex F; Gérard JP; Chauffert B; Brun M
    Ann Chir; 2000 Feb; 125(2):111-7. PubMed ID: 10998795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?
    Mandalà M; Moro C; Labianca R; Ferretti G
    J Clin Oncol; 2007 Sep; 25(27):4320-1; author reply 4321-2. PubMed ID: 17878488
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.